April 11, 2011 (Berlin, Germany) — Pegylated interferon lambda (Peg-IFN lambda) showed virological responses superior to the standard of care, pegylated interferon alfa-2a (Peg-IFN alfa-2a), when ...

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma Seventy-nine patients (40 with PV and 39 with ET) have ...

April 18, 2005 — The bioadjuvant combination of interferon alfa-2a, isotretinoin, and vitamin E improves survival for patients with squamous cell carcinoma of the head and neck (SCCHN), according to ...

Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status A total of 189 ...

Please provide your email address to receive an email when new articles are posted on . The combination of ruxolitinib and pegylated interferon alpha-2a exhibited encouraging activity among patients ...

Please provide your email address to receive an email when new articles are posted on . Study results suggest that combination bulevirtide 10 mg with PEG-IFN a-2a was superior to bulevirtide ...

IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. Roferon-A is an injectible, ...

IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. Roferon-A is an injectible, ...

Chronic infection with hepatitis B virus and hepatitis delta virus (HDV) results in the most severe form of viral hepatitis. There is no currently approved treatment. We investigated the safety and ...

Weekly peginterferon alfa-2a therapy, with or without daily adefovir, cleared hepatitis D virus (HDV) RNA in about one quarter of patients who participated in the Hep-Net-International Delta Hepatitis ...

Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (ABUS) (“Arbutus” or the “Company ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...